RTI Biologics, an Alachua, Fla.-based provider of orthopedic and biologic implants, reported revenues of $45.4 million for the fourth quarter of 2010, an 8 percent increase over the fourth quarter of 2009, according to a company news release.
Brian K. Hutchinson, chairman and CEO of RTI Biologics, attributes the company's success to a strong demand at the end of the year resulting from increased case volumes. The company has also focused on increasing operating cash flow and inventory reductions, which strengthened the balance sheet.
Domestic revenues for the fourth quarter were reported as $41.1 million, a 15 percent increase over the fourth quarter of last year. The international revenues decreased by 30 percent, at $4.3 million, due to declines in dental revenue and continued economic weakness in several international markets.
The company reported sales of $12.3 million in sports medicine, $9.4 million in spine and $5.68 million in general orthopedics during the fourth quarter.
Read the RTI Biologics release on the 4Q FY 2010 financial report.
Read other coverage on RTI Biologics:
- RTI Biologics Named Stryker's Dean Bergy to Board of Directors
- RTI Biologics Reports Total Revenue of $41.8M, 2% Decrease
Brian K. Hutchinson, chairman and CEO of RTI Biologics, attributes the company's success to a strong demand at the end of the year resulting from increased case volumes. The company has also focused on increasing operating cash flow and inventory reductions, which strengthened the balance sheet.
Domestic revenues for the fourth quarter were reported as $41.1 million, a 15 percent increase over the fourth quarter of last year. The international revenues decreased by 30 percent, at $4.3 million, due to declines in dental revenue and continued economic weakness in several international markets.
The company reported sales of $12.3 million in sports medicine, $9.4 million in spine and $5.68 million in general orthopedics during the fourth quarter.
Read the RTI Biologics release on the 4Q FY 2010 financial report.
Read other coverage on RTI Biologics:
- RTI Biologics Named Stryker's Dean Bergy to Board of Directors
- RTI Biologics Reports Total Revenue of $41.8M, 2% Decrease